Projecten per jaar
Vingerafdruk
- 1 Soortgelijke profielen
Netwerk
Projecten
- 3 Actief
-
OZR3913: Cofinanciering OZR FWO Hercules MZW - Single-cell eiwit analyse in intacte weefsels
Movahedi, K., van Grunsven, L., Rooman, I., Van Ginderachter, J., Smolders, I., Neyns, B., Vanhaecke, T., Laoui, D., Breckpot, K., De Veirman, K., Stijlemans, B., Van Schependom, J., Magez, S., Goyvaerts, C., De Kock, J., De Leu, N., Massie, A., Hellemans, K., Spits, C., De Bundel, D., De Trez, C., Hernot, S., Van Dooren, S., Aerts, J., Staels, W. & Tuyaerts, S.
25/02/22 → 25/02/26
Project: Fundamenteel
Onderzoeksoutput
-
790 Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab
Tijtgat, J., Schwarze, J. K., Vander Mijnsbrugge, A-S., Raeymaeckers, S., Van Riet, I., Geeraerts, X., Stevens, L., Tuyaerts, S. & Neyns, B., 7 nov 2022, In: Journal for immunotherapy of cancer. 10, Suppl 2Onderzoeksoutput: Meeting abstract (Journal)
Open Access -
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB)
Schwarze, J. K., Geens, W., Tijtgat, J., Awada, G., Seynaeve, L., Vanbinst, A-M., Everaert, H., Michotte, A., Bruneau, M., Van Riet, I., Tuyaerts, S., Duerinck, J. & Neyns, B., 1 jun 2022, In: Journal of Clinical Oncology. 40, 16, 2033.Onderzoeksoutput: Meeting abstract (Journal)
-
Early interim results from a randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in non-small cell lung cancer (NSCLC)
Tijtgat, J., Schwarze, J. K., Vandenbroucke, F., Ilsen, B., Tuyaerts, S., Dufait, I., Decoster, L., De Ridder, M. & Neyns, B., 22 sep 2022.Onderzoeksoutput: Poster
-
Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
Schwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Vasaturo, A., Bagnall, C., Forsyth, R., Dufait, I., Tuyaerts, S., Van Riet, I. & Neyns, B., sep 2022, In: Journal for immunotherapy of cancer. 10, 9, blz. 1-13 13 blz., e005141.Onderzoeksoutput: Article › peer review
Open Access -
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
De Jaeghere, E. A., Tuyaerts, S., Van Nuffel, A. M. T., Belmans, A., Bogaerts, K., Baiden-Amissah, R., Lippens, L., Vuylsteke, P., Henry, S., Trinh, X. B., van Dam, P. A., Aspeslagh, S., De Caluwé, A., Naert, E., Lambrechts, D., Hendrix, A., De Wever, O., Van de Vijver, K. K., Amant, F., Vandecasteele, K. & 1 anderen, , 12 aug 2022, In: Cancer Immunol Immunother.Onderzoeksoutput: Article › peer review
Open Access2 Citaten (Scopus)
-
Human relevant models for drug research and development
Fien Meeus (Speaker), Robin Maximilian Awad (Contributor), Nick Devoogdt (Contributor), Sandra Tuyaerts (Contributor), Cleo Goyvaerts (Contributor), Yannick De Vlaeminck (Contributor), Bart Neyns (Contributor) & Karine Breckpot (Contributor)
8 okt 2021Activiteit: Talk or presentation at a workshop/seminar
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor) & Bart Neyns (Contributor)
17 sep 2021Activiteit: Talk or presentation at a conference